文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

确定pacritinib推荐剂量:PAC203晚期骨髓纤维化剂量探索试验结果

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis.
PubMed 文献 · Blood Adv · 2020-01-01

PAC203是一项随机剂量探索研究,纳入161例对ruxolitinib不耐受或耐药的晚期骨髓纤维化患者,随机接受pacritinib 100 mg每日一次、100 mg每日两次或200 mg每日两次。结果显示200 mg每日两次组脾脏体积应答率最高(9.3%),尤其在基线血小板<50×10^3/μL患者中达17%,且未增加≥3级出血或心脏事件,被选为关键III期研究推荐剂量。

要点

  • pacritinib 200 mg每日两次在晚期骨髓纤维化中显示最高脾脏体积应答率。
  • 基线血小板<50×10^3/μL患者中200 mg每日两次的SVR率达17%。
  • 200 mg每日两次未增加≥3级出血或心脏事件,安全性可接受。

核心结论

  • pacritinib 200 mg每日两次在晚期骨髓纤维化患者中显示临床活性且安全性可接受,被选为关键III期研究的推荐剂量。

研究设计与样本

  • 随机剂量探索研究,161例对ruxolitinib不耐受或耐药的晚期骨髓纤维化患者按1:1:1随机接受pacritinib 100 mg每日一次、100 mg每日两次或200 mg每日两次。

主要发现

  • 脾脏体积应答率(SVR)在200 mg每日两次组最高(9.3%),100 mg每日两次组为1.8%,100 mg每日一次组为0%。
  • 基线血小板<50×10^3/μL患者中,200 mg每日两次组SVR率为17%(4/24)。
  • 总症状评分(TSS)应答率在各剂量组相似(100 mg每日一次7.7%、100 mg每日两次7.3%、200 mg每日两次7.4%),但TSS中位百分比降低呈剂量反应关系(-3%、-16%、-27%)。
  • 基于全部数据的药代动力学和药效学模型显示200 mg每日两次的SVR和TSS降低最大。
  • 常见不良事件为胃肠道事件、血小板减少和贫血;200 mg每日两次未增加≥3级出血或心脏事件。

关键数值与推荐

  • 脾脏体积应答定义为≥35% SVR,总症状应答定义为7项TSS降低≥50%,均评估至第24周。
  • 严重血小板减少(血小板计数<50×10^3/μL)见于44%的患者。
  • 73%的患者对ruxolitinib不耐受,76%耐药,50%同时满足两者。

临床怎么用

  • 对于对ruxolitinib不耐受或耐药的晚期骨髓纤维化患者,尤其是合并严重血小板减少者,可考虑pacritinib 200 mg每日两次。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PAC203 is a randomized dose-finding study of pacritinib, an oral JAK2/IRAK1 inhibitor, in patients with advanced myelofibrosis who are intolerant of or resistant to ruxolitinib. Patients were randomized 1:1:1 to pacritinib 100 mg once per day, 100 mg twice per day, or 200 mg twice per day. Enhanced eligibility criteria, monitoring, and dose modifications were implemented to mitigate risk of cardiac and hemorrhagic events. Efficacy was based on ≥35% spleen volume response (SVR) and ≥50% reduction in the 7-component total symptom score (TSS) through week 24. Of 161 patients, 73% were intolerant of and 76% had become resistant to ruxolitinib; 50% met criteria for both. Severe thrombocytopenia (platelet count <50 × 103/μL) was present in 44%. SVR rates were highest with 200 mg twice per day (100 mg once per day, 0%; 100 mg twice per day, 1.8%; 200 mg twice per day, 9.3%), particularly among patients with baseline platelet counts <50 × 103/μL (17%; 4 of 24). Although TSS response rate was similar across doses (100 mg once per day, 7.7%; 100 mg twice per day, 7.3%; 200 mg twice per day, 7.4%), median percent reduction in TSS suggested a dose-response relationship (-3%, -16%, and -27%, respectively). Pharmacokinetic and pharmacodynamic modeling based on all available data showed greatest SVR and TSS reduction at 200 mg twice per day compared with lower doses. Common adverse events were gastrointestinal events, thrombocytopenia, and anemia. There was no excess of grade ≥3 hemorrhagic or cardiac events at 200 mg twice per day. Pacritinib 200 mg twice per day demonstrated clinical activity and an acceptable safety profile and was selected as the recommended dose for a pivotal phase 3 study in patients with myelofibrosis and severe thrombocytopenia. This trial was registered at www.clinicaltrials.gov as #NCT03165734.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Gerds AT, Savona MR, Scott BL, et al. Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. Blood Adv. 2020. PMID: 33232476. doi:10.1182/bloodadvances.2020003314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。